CORDIS
EU research results

CORDIS

English EN

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Project information

Grant agreement ID: 858070

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 021 968,60

  • EU contribution

    € 4 021 968,60

Coordinated by:

UNIVERSITEIT ANTWERPEN

Belgium

Project description

English EN

Enhancing prediction of severe adverse effects early in the drug development pipeline

Around 9 of every 10 drug candidates fail to win approval. Drugs can often progress into phase III clinical trials - trials with patients - before some rare but potentially lethal side effects become apparent. This late-stage discovery has significant consequences for the time and cost of drug development. Safety pharmacology is a rapidly developing discipline that seeks to predict whether a drug is likely to be found unsafe if administered to human beings. INSPIRE plans to advance the field of safety pharmacology with a focus on cardiovascular events. Bringing together interrelated expertise including academics, pharmaceutical companies, hospitals, and regulators, the team is fostering innovation among early stage researchers to detect and minimise cardiovascular adverse events early in the pipeline.

Coordinator

UNIVERSITEIT ANTWERPEN

Address

Prinsstraat 13
2000 Antwerpen

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 768 960

Participants (9)

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 531 239,76

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

EU Contribution

€ 606 345,12

INSTITUT NATIONAL DE RECHERCHE ENINFORMATIQUE ET AUTOMATIQUE

France

EU Contribution

€ 274 802,04

NCARDIA BV

Netherlands

EU Contribution

€ 265 619,88

UCB BIOPHARMA SRL

Belgium

EU Contribution

€ 256 320

NOTOCORD SYSTEMS

France

EU Contribution

€ 549 604,08

TSE SYSTEMS GMBH

Germany

EU Contribution

€ 252 788,40

BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

Germany

EU Contribution

€ 252 788,40

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 263 500,92

Project information

Grant agreement ID: 858070

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2023

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 4 021 968,60

  • EU contribution

    € 4 021 968,60

Coordinated by:

UNIVERSITEIT ANTWERPEN

Belgium